- Home
- IMAB vs AVTX Comparison
IMAB vs AVTX Comparison
Compare IMAB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- AVTX
- Stock Information
- Founded
- IMAB 2014
- AVTX 2011
- Country
- IMAB United States
- AVTX United States
- Employees
- IMAB N/A
- AVTX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- AVTX Health Care
- Exchange
- IMAB Nasdaq
- AVTX Nasdaq
- Market Cap
- IMAB 486.4M
- AVTX 248.3M
- IPO Year
- IMAB 2020
- AVTX 2015
- Fundamental
- Price
- IMAB $4.64
- AVTX $18.38
- Analyst Decision
- IMAB Strong Buy
- AVTX Strong Buy
- Analyst Count
- IMAB 6
- AVTX 9
- Target Price
- IMAB $7.50
- AVTX $30.14
- AVG Volume (30 Days)
- IMAB 2.2M
- AVTX 406.9K
- Earning Date
- IMAB 11-14-2025
- AVTX 11-07-2025
- Dividend Yield
- IMAB N/A
- AVTX N/A
- EPS Growth
- IMAB N/A
- AVTX N/A
- EPS
- IMAB N/A
- AVTX N/A
- Revenue
- IMAB N/A
- AVTX $441,000.00
- Revenue This Year
- IMAB N/A
- AVTX N/A
- Revenue Next Year
- IMAB N/A
- AVTX N/A
- P/E Ratio
- IMAB N/A
- AVTX N/A
- Revenue Growth
- IMAB N/A
- AVTX N/A
- 52 Week Low
- IMAB $0.60
- AVTX $3.39
- 52 Week High
- IMAB $6.79
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- IMAB 48.87
- AVTX 70.82
- Support Level
- IMAB $4.13
- AVTX $16.77
- Resistance Level
- IMAB $6.79
- AVTX $19.20
- Average True Range (ATR)
- IMAB 0.67
- AVTX 1.56
- MACD
- IMAB -0.14
- AVTX 0.25
- Stochastic Oscillator
- IMAB 19.17
- AVTX 83.52
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).